Eurycomanone induces apoptosis through the up-regulation of p53 in human cervical carcinoma cells

Journal of Cancer Molecules

Volumn 4, Issue 4, 2008, Pages 109-115

  Mahfudh, Nurkhasanah ^a,b   Pihie, Azimahtol Hawariah Lope ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITAS AHMAD DAHLAN   (Indonesia)

Author keywords

Apoptosis; Bax; Eurycomanone; p53

Indexed keywords

CYTOTOXIC AGENT; EURYCOMANONE; METHYLENE BLUE; PROTEIN BAX; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA FRAGMENTATION; DRUG EFFICACY; EURYCOMA; EURYCOMA LONGIFOLIA; HUMAN; HUMAN CELL; IC 50; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; UPREGULATION; UTERINE CERVIX CARCINOMA;

EID: 63049114534     PISSN: 18160735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol: Hematol 33: 169-185, 2000.
2. National Cancer Registry Ministry of Health Malaysia. Second report of the National Cancer Registry cancer incidence in Malaysia 2003.
3. Finzer P, Aguilar-Lemarroy A, Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett 188: 15-24, 2002.
4. Choi JW, Ahn WS, Bae SM, Lee DB, Kim YW. Adenoviral p53 effects and cell-specific E7 protein-protein interactions of human cervical cancer cells. Biosen Bioelectron 20: 2236-2243, 2005.
5. Horner SM, DeFilippis RA, Manuelidis L, DiMalo D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma. J Virol 78: 4063-4073, 2004.
6. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
7. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20: 7874-7887, 2001.
8. Munger K, Basile JR, Duensing S, Eichten A, Gonzales SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898, 2001.
9. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62: 7364-7371, 2002.
10. Yim EK, Lee KH, Bae JS, Namkoong SE, Um SJ, Park JS. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol 23: 769-776, 2004.
11. Kuo PC, Damu AG, Lee KH, Wu TS. Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorganic Med Chem 12: 537-544, 2004.
12. Kardono LBS, Angerhofer CK, Tsauri S, Padmawinata K, Pezzuto JM, Kinghorn AD. Cytotoxic and antimalarial constituents of the roots of Eurycoma longifolia. J Nat Prod 54: 1360-137, 1991.
13. Darise M, Kohda H, Mizutani K, Tanaka O. Eurycomanone and Eurycomanol, quassinoids from the roots of Eurycoma longifolia. Phytochemistry 21: 2091-2093, 1982.
14. Morita H, Kishi E, Takeya K, Itokawa H, Tanaka O. New quassinoids from roots of Eurycoma longifolia. Chem lett 5: 749-752, 1990.
15. Morita H, Kishi E, Takeya K, Itokawa H, Iitaka Y. Highly oxygenated quassinoids from Eurycoma longifolia. Phytochemistry 33: 691-696, 1992.
16. Itokawa H, Qin XR, Morita H, Takeya K, Iitaka Y. Novel quassinoids from Eurycoma longifolia. Chem Pharm Bull 41: 403-405, 1993.
17. Itokawa H, Qin XR, Morita H, Takeya K. C18 and C19 quassinoids from Eurycoma longifolia. J Nat Prod 56: 1766-1771, 1993.
18. Itokawa H, Kishi E, Morita H, Takeya K. Cytotoxic quassinoids tirucallane-type triterpenes from the woods of Eurycoma longifolia. Chem Pharm Bull 40: 1035-1055, 1992.
19. Chan KL, Lee SP, Sam TW, Tan SC, Noguchi H, Sankawa U. 13-, 18-dihydroeurycomanol, a quassinoid from Eurycoma longifolia. Phytochemistry 30: 3138-3141, 1991.
20. Chan KL, Itaka Y, Noguchi H, Sugiyama H, Saito I, Sankawa U. 6-hydroxyeurycomalactone, a quassinoid from Eurycoma longifolia. Phytochemistry 31: 4295-4298, 1992.
21. Ang HH, Hitotsuyanagi Y, Takeya K. Eurycolactone A-C, novel quasinoids from Eurycoma longifolia. Tetrahedron Lett 41: 6849-6853, 2000.
22. Ang HH, Hitotsuyanagi Y, Fukaya H, Takeya K. Quassinoids from Eurycoma longifolia. Phytochemistry 59: 833-837, 2002.
23. Mitsunaga K, Koike K, Tanaka T, Ohkawa Y, Kobayashi Y, Sawaguchi T, Ohmoto T. Canthin-6-one alkaloids from Eurycoma longifolia. Phytochemistry 35: 799-802, 1994.
24. Morita H, Kishi E, Takeya K, Itokawa H, Iitaka Y. Squalene derivatives from Eurycoma longifolia. Phytochemistry 34: 765-771, 1993.
25. Morita H, Kishi E, Takeya K, Itokawa H. Biphenylneolignans from wood of Eurycoma longifolia. Phytochemistry 31: 3993-3995, 1992.
26. Tee TT, Azimahtol HLP. Induction of apoptosis by Eurycoma longifolia Jack extract, Anticancer Res 25: 2205-2214, 2005.
27. Cheah SC, Azimahtol HLP. Eurycomanone exert antiproliferative activity via apoptosis upon MCF-7 cells. Proc Sym Biol Kebangsaan Malaysia ke-7: 73-77, 2004.
28. Chan KL, O'Neill MJ, Phollopson JD, Warhurst DC. Plant as source of antimalarial drugs. Planta Medica 52: 105-107, 1986.
29. Lee ATC, Azimahtol HLP. Styrylpirone derivatives induce apoptosis through the up-regulation of Bax in human breast cancer cell lines MCF-7. J Biochem Mol Biol 36: 269-274, 2003.
30. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, Fujii T. Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274: 37461-37466, 1999.
31. Dibartolomeis SM, Moné JP. Apoptosis: a four week laboratory investigation for advanced molecular and cellular biology students. Cell Biol Edu 7242F: 275-295, 2003.
32. Brown LR. Laboratory exercise: A laboratory exercise in comparative DNA analysis. Biochem Mol Biol Edu 31: 177-179, 2003.
33. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 407: 784-788, 2000.
34. Lawen A. Apoptosis-an introduction. BioEssay 25: 888-896, 2003.
35. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
36. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602: 47-59, 2002.
37. Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 53: 121-133, 1997.
38. Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Pezzuto JM, Udeani GO, Wani MC, Wall ME, Navarro HA, Kramer RA, Menendez AT, Fairchild CR, Lane KE, Forenza S, Vyas DM, Lam KS, Shu YZ. Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl Chem 71: 1611-1618, 1999.
39. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
40. Allen RT, Hunter III WJ, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Method 37: 215-228, 1997.
41. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78: 129-139, 1998.
42. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Gene Dev 12: 2973-2983, 1998.
43. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing radiation and UV radiation. Mol Cell Biol 17: 355-363, 1997.
44. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999.
45. Ismail N, Azimahtol HLP, Nallapan M. Xanthorrhizol induces apoptosis via the up-regulation of Bax and p53 in HeLa cells. Anticancer Res 25: 2221-2228, 2005.
46. Bernard B, Pretet JL, Charlot JF, Mougin C. Human papilloma virus type 16+ and 18+ cervical carcinoma cells are sensitive to staurosporine-mediated apoptosis. Biol Cell 95: 17-26, 2003.
47. Zheng PW, Chiang LC, Lin CC. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci 76: 1367-1379, 2005.
48. Reddy VG, Khanna N, Singh N. Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing p53. Biochem Biophys Res Commun 282: 409-415, 2001.
49. Singh S, Upadhyay AU, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis. FEBS Lett 581: 289-295, 2007.
50. Maldonado V, Melendez-Zajgla J, Ortega A. Modulation of NF-?B, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Mutation Res 381: 67-75, 1997.
51. Ceraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, Orvain C, Frebourg T, Klein-Soyer C, Bergerat JP. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 75: 432-438, 1998.
52. Concin N, Zeillinger C, Stimpfel M, Schiebel I, Tong D, Wolff U, Reiner A, Leodolter S, Zeillinger R. p53-dependent radioresistance in ovarian carcinoma cell lines. Cancer Lett 150: 191-199, 2000.
53. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton ML. Effect of p53 status on sensitivity to platinum complexes in human ovarian cancer cell line. Mol Pharmacol 57: 503-511, 2000.
54. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 55: 48-63, 1999.
55. Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death, Oncogene 18: 6145-6157, 1999.
56. Rapp L, Chen JJ. The papillomavirus E6 proteins. Biochim Biophys Acta 1378: F1-F19, 1998.
57. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98: 1218-1223, 2001.
58. Miyashita M, Krajewski S, Krajewska M, Wang HG, Lin HK, Libermann DA, Hoffmann B, Reed JC. Tumour suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
59. Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, Thongsuksai, P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gyn Oncol 94: 636-642, 2004.
60. Nair P, Nair MK, Jayaprakash PG, Pillai MR. Decreased programmed cell death in the uterine cervix associated with high risk human papilloma virus infection. Path Oncol Res 5: 95-103, 1999.